Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Abroad (travel likely)Recruiting

Conditions

Lupus Nephritis · ANCA Associated Vasculitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tongji Hospital, Wuhan, Hubei, China
Contact: Study coordinator (Lingli Dong, MD) · tjhdongll@163.com · 86-27-83665519
Contact: Study coordinator (Cong Ye, MD) · Yecong@163.com · 86-27-83665518

Study leads

Lingli Dong, MD
Principal Investigator
Tongji Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Lupus Nephritis

Abroad (travel likely)RecruitingPHASE3

Orchard Park, United States · Vitória, Brazil

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Lupus Nephritis

Abroad (travel likely)RecruitingPHASE2

Syracuse, United States · San Antonio, United States

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Lupus Nephritis

Abroad (travel likely)Recruiting

Baltimore, United States · Charlotte, United States

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

SLE · Systemic Lupus Erythematosus (SLE) · CAR T Cell

Abroad (travel likely)RecruitingPHASE1, PHASE2

Philadelphia, United States